Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
Investment Firms›
Bain Capital Life Sciences
AddedFeb 13, 2024
UpdatedJun 28, 2026
Bain Capital Life Sciences

Bain Capital Life Sciences

Operating

Bain Capital Life Sciences Fund LP: Boston-based buyout specialist in life sciences.

Location
Boston, MA, US
Founded
2016
Firm
Compare
Portfolio
Employees
Website

Bain Capital Life Sciences, based in Boston, Massachusetts, specializes in buyouts within the life sciences sector. The firm typically invests in Series A through Series D rounds, as well as post-IPO equity and private equity stages. Their investment focus spans biotechnology, pharmaceuticals, medical devices, and diagnostics, with a strong emphasis on companies that have raised significant capital, often in the range of tens to hundreds of millions of dollars.

Notable portfolio companies include 2seventy bio, Abcuro, Affinivax, and Freenome, among others. Bain Capital Life Sciences is known for its strategic resources and close partnerships with management teams to foster growth and innovation. Key decision-makers at the firm leverage their extensive experience and networks to provide unique value-add services, such as strategic guidance and operational support, ensuring that portfolio companies can thrive in competitive markets.

Bain Capital Life Sciences - Portfolio Snapshot

Portfolio activity breakdown across disclosed investments and stages

Total Investments51
Current Portfolio Count38
Total Portfolio Exits2

Top Investment Stages

Post Ipo Equity12 (27.3%)
Series B11 (25.0%)
Series C8 (18.2%)
Series D7 (15.9%)
Series A6 (13.6%)

Stage Mix

Post Ipo Equity 27%Series B 25%Series C 18%Series D 16%Series A 14%

Concentration shown as share of disclosed investments by stage.

Recent Investments

Syros Pharmaceuticals logo

Syros Pharmaceuticals

Aiolos Bio logo

Aiolos Bio

Nimbus Therapeutics logo

Nimbus Therapeutics

Abcuro logo

Abcuro

Adarx Pharmaceuticals logo

Adarx Pharmaceuticals

Kyverna Therapeutics logo

Kyverna Therapeutics

Upstream Bio logo

Upstream Bio

Alkeus Pharmaceuticals logo

Alkeus Pharmaceuticals

Heartflow logo

Heartflow

Jnana Therapeutics logo

Jnana Therapeutics

Emalex Biosciences logo

Emalex Biosciences

Solid Biosciences logo

Solid Biosciences

Rivus Pharmaceuticals logo

Rivus Pharmaceuticals

Areteia Therapeutics logo

Areteia Therapeutics

X4 Pharmaceuticals logo

X4 Pharmaceuticals

2seventy bio logo

2seventy bio

Freenome logo

Freenome

Cardurion Pharmaceuticals logo

Cardurion Pharmaceuticals

Tango Therapeutics logo

Tango Therapeutics

Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

Imperative Care logo

Imperative Care

Interius BioTherapeutics logo

Interius BioTherapeutics

Crinetics Pharmaceuticals logo

Crinetics Pharmaceuticals

River 2 Renal logo

River 2 Renal

River 3 Renal logo

River 3 Renal

Bain Capital Life Sciences - Similar Investment Firms

Mirae Asset Capital Life Science logo

Mirae Asset Capital Life Science

Bain Capital Tech Opportunities logo

Bain Capital Tech Opportunities

baincapital.com

Bay City Capital logo

Bay City Capital

baycitycapital.com

Ra Capital Management logo

Ra Capital Management

racap.com

Blackstone Life Sciences logo

Blackstone Life Sciences

blackstone.com

Bain Capital Credit logo

Bain Capital Credit

baincapital.com

Mass Medical Angels logo

Mass Medical Angels

massmedangels.com

BioInnovation logo

BioInnovation

Bain Capital Ventures logo

Bain Capital Ventures

Amicus Capital Partners logo

Amicus Capital Partners

BioImpact Capital logo

BioImpact Capital

Foresite Capital logo

Foresite Capital

Biospring Partners logo

Biospring Partners

biospring.com

Boston Millennia Partners logo

Boston Millennia Partners

Banyan Pacific logo

Banyan Pacific

banyanpac.com

Bain Capital Life Sciences - Classification

Also Known As
  • Bain Capital Life Sciences, LP
NAICS
  • 520000Finance and Insurance
  • 523000Securities, Commodity Contracts, and Other Financial Investments and Related Activities
  • 523900Other Financial Investment Activities
  • 523990All Other Financial Investment Activities
  • 523999Miscellaneous Financial Investment Activities
SIC
  • 6700Holding And Other Investment Offices
  • 6720Investment Offices
  • 6722Management Investment Offices, Open-end
Show 2 more industry codes
NAICS
  • 525000Funds, Trusts, and Other Financial Vehicles
SIC
  • 6000Depository Institutions